122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I

Abstract

Cemi (anti-PD-1) used as monotherapy has been shown to improve overall survival (OS) vs chemo in patients (pts) with advanced NSCLC, no EGFR, ALK or ROS1 aberrations, and PD-L1 expression in ≥50% of tumor cells. Since the benefit of PD-(L)1 blockade decreases with decreased PD-L1 expression, combination therapies are required for tumors with low PD-L1. Both chemotherapy and anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have been shown to augment the effects of anti–PD-1 in pts with advanced NSCLC.